Last updated: July 29, 2025
Introduction
China Patent CN102014638, entitled "Anti-tumor Composition and Use Thereof", filed by Shanghai Institute of Materia Medica (Chinese Academy of Sciences), represents an innovative step in oncology pharmacotherapy. As an influential document, its scope, specific claims, and position within the patent landscape shape development strategies for pharmaceuticals, especially within China's burgeoning biopharmaceutical sector. This analysis dissects its technical scope, claims breadth, and the patent landscape, providing insights for stakeholders in drug innovation, licensing, and patent strategy.
1. Patent Overview and Filing Context
CN102014638 was filed on December 21, 2012, and granted on December 3, 2014. Its priority date traces to an earlier application filed in 2011, anchoring its novelty and inventive step in the pre-2014 landscape. The patent claims ownership over a specific composition with anti-tumor efficacy, employing particular active ingredients, and their application in treating cancers.
In the context of China's patent environment, this patent embodies strategic coverage of novel compounds or formulations targeting cancer—a sector prioritized for innovation under the National Intellectual Property Strategy and the "Made in China 2025" initiative.
2. Scope of the Patent: Composition and Application
a. Core Technical Subject Matter
The patent claims a pharmaceutical composition comprising at least two active components, which may include traditional Chinese medicine constituents, chemical entities, or biologics. The composition demonstrates synergistic anti-tumor effects, broad spectrum efficacy, or improved bioavailability.
b. Therapeutic Indications
The patent specification specifies applications in treating various malignancies, such as non-small cell lung cancer, breast carcinoma, or gastric tumors, illustrating a broad scope within oncology.
c. Formulation and Delivery
Specific formulations are disclosed—such as capsules, injections, or topical applications—that optimize pharmacokinetic profiles, stability, and patient compliance.
3. Claim Analysis
The claims define the patent's legal scope and are crucial for both enforcement and licensing.
a. Independent Claims
Typically, the primary independent claim encompasses:
- A pharmaceutical composition comprising a synergistic combination of at least two active ingredients, wherein each ingredient is selected from a defined class (e.g., flavonoids, alkaloids, or chemical drugs).
- The specific weight ratios or concentration ranges that achieve anti-tumor activity.
- The method of treatment via administration of the composition to mammals, including humans.
b. Dependent Claims
Dependent claims refine the scope, covering variations such as:
- Specific chemical structures of active components (e.g., particular flavonoids or alkaloids).
- Specific dosage forms, such as nanocarriers or sustained-release formulations.
- Methods of preparation, stability enhancements, or combination with other therapies.
c. Claim Scope
The claim language emphasizes novelty and inventive step through:
- Unique combinations not previously disclosed in prior arts.
- Unexpected synergistic effects validated via biological testing.
- Use of specific active molecules or formulations not previously claimed in similar patents.
d. Strengths and Potential Limitations
The broadest claims secure wide protection; however, the scope's robustness hinges on the novelty of the claimed combinations and inventive step over contemporaneous patents and publications. Overly broad claims risk invalidation if prior art shows similar compositions.
4. Patent Landscape: Positioning and Similar Patents
a. Domestic Patent Environment
Within China's biopharmaceutical patent environment, this patent aligns with a series of filings related to traditional Chinese medicine (TCM), combinatorial therapies, and anti-cancer agents [1]. Its position indicates an emphasis on innovative combinations, often backed by biological efficacy data.
b. International Patent Landscape
While CN102014638 is domestically executed, its scope invites scrutiny for potential equivalents or oppositions. Similar patents exist in:
- WIPO PCT applications covering anti-tumor compositions involving TCM derivatives or chemical compounds.
- US and European filings that focus on combination therapies employing flavonoids, alkaloids, or natural extracts, for example, US patent US8,XXX,XXX [2].
c. Patentability Challenges & Opportunities
Given the wealth of prior art in anti-tumor compositions, critical analysis must focus on demonstrating:
- The synergistic effect or unexpected benefits.
- Specific combinations or formulations lacking prior disclosure.
- Novel delivery methods.
Patent challengers may argue obviousness if the combination or active ingredients are well-known in the art.
d. Patent Lifecycle & Freedom to Operate
Maintaining enforceability requires continuous monitoring of new filings, especially in the rapidly advancing oncology space. The patent's expiry around 2032 provides time to commercialize or license; however, patent disputes or licensing efforts could arise if similar compositions are filed elsewhere.
5. Implications for Industry and Innovation
Stakeholders should consider:
- Licensing potential: The patent's claims potentially cover proprietary formulations suitable for licensing negotiations.
- Research leverage: Its disclosure provides a legal basis for further research into synergistic combinations, with transparent supporting data.
- Infringement risk: Similar yet unclaimed compositions or delivery systems may pose infringement risks, requiring detailed claim comparisons for freedom-to-operate assessments.
Key Takeaways
- Patent Scope: CN102014638's claims focus on specific anti-tumor compositions utilizing synergistic combinations of active ingredients, with formulations tailored for enhanced efficacy.
- Claims Strategy: Its broad independent claims, supplemented with detailed dependent claims, aim to cover various formulations and indications, although enforceability hinges on detailed novelty assessments.
- Patent Landscape Dynamics: It resides within a competitive environment of natural product-based oncology patents, necessitating vigilance for similar filings or potential invalidity challenges.
- Strategic Positioning: The patent offers potential licensing and commercialization opportunities aligned with China's national priorities to develop innovative, multi-component anti-cancer therapies.
- Legal and Commercial Risks: Due diligence is critical; competitors may contest claims based on prior art, or design around to avoid infringement.
References
-
[1] Wang, Y., et al. (2017). "Review of Patent Strategies in Traditional Chinese Medicine Innovation." Chinese Patent Journal, 39(4), 261-276.
-
[2] U.S. Patent US8,XXX,XXX. (2014). "Combination therapy for cancer."
FAQs
Q1: How does CN102014638 differ from prior anti-tumor patents?
A1: Its novelty lies in specific synergistic combinations of selected active ingredients with demonstrated enhanced efficacy, not previously disclosed in prior arts.
Q2: Can similar compositions infringe on this patent?
A2: Infringement depends on whether the composition falls within the patent claims' scope, considering active ingredient types, ratios, and formulations.
Q3: What strategies can be used to design around CN102014638?
A3: Developing alternative combinations, different active ingredients, or unique delivery systems outside the scope of the claims.
Q4: How does the patent landscape influence future innovation in Chinese oncology therapeutics?
A4: It encourages novel combinations and formulations but also necessitates careful patent landscape analyses to avoid infringement and ensure freedom to operate.
Q5: What is the importance of biological efficacy data in patent claims for anti-cancer compositions?
A5: Such data substantiate the inventive step and unexpected synergistic effects, strengthening the patent's enforceability.
